Welcome to our dedicated page for MAIA Biotechnology SEC filings (Ticker: MAIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. director Louie Ngar Yee reported a grant of 25,331 stock options on 10/02/2025. The options have an exercise price of $1.80, vest 100% immediately on the grant date, are exercisable immediately, and expire on 10/02/2035. The Form 4 indicates the filing was completed on 10/06/2025 and the reporting person is filing individually as a director. The grant was made under the company’s 2021 Equity Incentive Plan and represents a direct beneficial ownership of 25,331 shares upon exercise.
MAIA Biotechnology, Inc. director Ramiro Guerrero was granted 20,459 stock options on 10/02/2025 under the 2021 Equity Incentive Plan. The options are exercisable immediately and vest 100% on the grant date, giving the holder the right to buy 20,459 shares of common stock. The reported conversion/exercise price is $1.80 per share and the options expire on 10/02/2035. Following this transaction, the reporting person beneficially owns 20,459 derivative shares as disclosed on the Form 4.
MAIA Biotechnology director Steven M. Chaouki received a grant of 20,946 stock options under the 2021 Equity Incentive Plan. The options are exercisable immediately, vesting 100% on grant, and carry an exercise price of $1.8 per share. The award represents a direct ownership interest of 20,946 shares underlying common stock following the transaction. The options expire ten years from grant and were reported on the required Form 4 filing.
This action increases the director's potential economic exposure to the company’s common stock and creates a near-term option position that could be exercised to acquire shares at the stated exercise price.
Stan V. Smith, a director of MAIA Biotechnology, Inc. (MAIA), purchased 19,230 shares of common stock on 10/01/2025 at a price of $1.30 per share under a Securities Purchase Agreement and the company’s 2021 Equity Incentive Plan. The transaction increased beneficial ownership to 1,324,289 shares, held indirectly through The Stan V. Smith Trust Dated 1993. In the same transaction Mr. Smith acquired 19,230 warrants (treated as options) with a $1.57 exercise price; those options become exercisable six months after issuance and expire three years after issuance (exercise window: 04/01/2026 through 10/01/2028). The Form 4 was signed on 10/02/2025.
MAIA Biotechnology reported a material financing-related disclosure. The Board approved director participation in a Private Placement to align director and stockholder interests. A director, Stan Smith, executed a Purchase Agreement to subscribe for 19,230 shares of common stock at $1.30 per share for an aggregate of approximately $25,000 and received warrants to purchase up to 19,230 shares exercisable at $1.57 beginning six months after issuance with a three-year term. The Director Shares and Director Warrants are being issued under the Company’s 2021 Equity Incentive Plan as an Unrestricted Stock Award and an Award of Options. Separately, the company amended certain common stock purchase warrants originally issued February 24, 2025 to reduce the exercise price from $1.87 to $1.30 for warrants to purchase 1,396,667 shares, including amendments affecting FGMK Holdings LLC for warrants to purchase 1,350,000 shares. Several related forms and a press release are filed as exhibits.
MAIA Biotechnology announced that it has been awarded a $2.3 million grant from the National Institutes of Health. The funding is designated to expand its THIO-101 Phase 2 clinical trial, which is evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer. This grant supports further clinical development of the program without relying on equity financing. The company provided more details in a press release attached as an exhibit.
MAIA Biotechnology, Inc. entered into inducement letter agreements with several accredited investors holding existing warrants to buy its common stock. These investors agreed to exercise warrants for a total of 440,503 shares of common stock (the “Exercise Shares”) at a reduced cash exercise price of $1.30 per share. In return, MAIA expects to receive approximately $572,654 in gross proceeds before expenses.
The Exercise Shares will be issued as restricted securities on or about the stated closing date and will not be registered under the Securities Act, bearing a restrictive legend. MAIA states that it intends to use the net proceeds from these warrant exercises for general corporate purposes. The company relies on exemptions from registration, including Section 4(a)(2), Rule 506 and/or Section 3(a)(9) of the Securities Act, for this private issuance.
MAIA Biotechnology, Inc. entered into inducement letter agreements with several accredited investors holding existing warrants to buy its common stock. These investors agreed to exercise warrants for a total of 440,503 shares of common stock (the “Exercise Shares”) at a reduced cash exercise price of $1.30 per share. In return, MAIA expects to receive approximately $572,654 in gross proceeds before expenses.
The Exercise Shares will be issued as restricted securities on or about the stated closing date and will not be registered under the Securities Act, bearing a restrictive legend. MAIA states that it intends to use the net proceeds from these warrant exercises for general corporate purposes. The company relies on exemptions from registration, including Section 4(a)(2), Rule 506 and/or Section 3(a)(9) of the Securities Act, for this private issuance.
MAIA Biotechnology, Inc. filed a current report to note that it has posted an updated presentation about its business on its website. The slide deck, filed as Exhibit 99.1 and incorporated by reference, is intended to provide summary information alongside the company’s other SEC filings and public announcements. The company states that the presentation speaks only as of the report date and that it does not undertake an obligation to update it. The materials contain forward-looking statements, and investors are cautioned not to place undue reliance on those statements.
MAIA Biotechnology filed an 8-K to share that it issued a press release announcing positive efficacy data from its THIO-101 Phase 2 clinical trial in non-small cell lung cancer. This suggests the company is seeing encouraging signals from THIO-101 in a difficult-to-treat cancer setting, although detailed results are contained in the attached press release rather than this summary document.
The company also includes standard cautionary language that these are forward-looking statements and that actual outcomes may differ due to clinical, regulatory, manufacturing, market acceptance, and intellectual property risks. No financial figures or commercial timelines are discussed in this filing.
MAIA Biotechnology, Inc. filed a current report describing new clinical data communication activities. The company prepared a scientific poster showing efficacy data from its Phase 2 THIO-101 trial, which evaluates THIO given in sequence with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer who had already failed two or more standard-of-care treatments.
The poster was selected as an abstract titled “Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS” and was presented at the 2025 IASLC World Conference on Lung Cancer on September 7, 2025. MAIA plans to post the same poster on its website on September 8, 2025 and has filed it as Exhibit 99.1 to this report. The company notes that the poster includes forward-looking statements and cautions investors not to place undue reliance on them.